Clinical Trials Logo

Clinical Trial Summary

Infection with dengue viruses is one of the leading causes of hospitalization and death in children in several tropical Asian counties. The World Health Organization (WHO) estimates that these viruses are responsible for more than 50 million cases of dengue fever (DF) and approximately 0.5 million cases of the more severe disease, dengue hemorrhagic fever/ shock syndrome (DHF/DSS) annually. Because dengue viruses are endemic in most tropical and subtropical regions, keeping more than 2 billion persons at risk for acquiring dengue, the WHO has made development of a dengue vaccine a top priority.

The purpose of this study is to evaluate the safety and effectiveness of a candidate DEN4 vaccine aimed at preventing infection with dengue virus serotype 4.


Clinical Trial Description

Dengue viruses are endemic in most tropical and subtropical regions of the world with more than 2 billion persons at risk for acquiring dengue. There are four serotypes of dengue virus (DEN 1, DEN 2, DEN 3, and DEN 4) each capable of causing dengue illness ranging from mild, self-limited febrile illness to life-threatening disease. Because previous infection with one dengue serotype can increase the risk for DHF/DSS following infection with a different serotype, immunization would ideally provide immunity against all four dengue viral serotypes.

Several live, attenuated dengue vaccines have been tested in Phase I and/or Phase II clinical trials. Although some have appeared promising in early trials, none have been able to meet the requirements for a safe and effective vaccine. Meeting these requirements has been particularly difficult when testing vaccines containing all four serotypes. The vaccine candidate in this study is live-attenuated rDEN4delta30, which will target the DEN4 serotype, it is a potential component for a future tetravalent dengue vaccine.

This is a double-blind, random assignment, placebo-controlled study in healthy, adult volunteers. The purpose of this study is to evaluate the safety and effectiveness of a single dose of DEN4 vaccine. Some participants will be receiving placebo as a comparative measure, to better assess vaccine-associated versus non vaccine-associated adverse events.

To qualify for participation in the study, volunteers will undergo an eligibility screening which will include medical history, physical exam, hematology testing, liver and renal function testing, coagulation studies, human immunodeficiency virus (HIV) and hepatitis B and C screening, urinalysis, and screening for pervious flavivirus infection. Urine pregnancy testing will also be required for female volunteers.

Duration of individual participation in the study is approximately 26 weeks following vaccination on Study Day 0. Volunteers will be randomly assigned to receive either rDEN4delta30 or placebo; 50 participants will receive the vaccine, 20 will receive placebo. On the day of vaccination, all volunteers will be reassessed by study personnel to ensure continued eligibility, vital signs will be taken, and a physical exam will be performed. Female participants will also have a pregnancy test and review of acceptable pregnancy prevention methods. Eligible participants will receive a vaccination of Study Day 0, followed by a 30 minute post vaccination assessment for adverse events. After vaccination, volunteers will be evaluated in the clinic approximately every other day for the first 16 days if study.

During the course of study, volunteers will have blood drawn and clinical evaluations performed on Study Days 21, 28, 42, and 180 post-vaccination. All participants will be asked to record oral temperatures 3 times a day for the first 16 days post-vaccination. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention


Related Conditions & MeSH terms


NCT number NCT00919178
Study type Interventional
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status Completed
Phase Phase 1
Start date July 2009
Completion date May 2010

See also
  Status Clinical Trial Phase
Completed NCT01436396 - Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Phase 3
Completed NCT03432442 - Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Phase 2
Completed NCT00788151 - Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Phase 2
Completed NCT01477671 - Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children N/A
Completed NCT01983553 - Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Completed NCT01134263 - Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Phase 3
Completed NCT02741128 - Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Phase 2
Completed NCT00993447 - Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Phase 2
Completed NCT01943825 - Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Phase 2
Completed NCT02979535 - Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Phase 3
Completed NCT02628444 - Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age Phase 2
Completed NCT01550289 - Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Phase 2
Completed NCT00875524 - Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Phase 2
Completed NCT00458120 - Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus Phase 1
Completed NCT01374516 - Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Phase 3
Completed NCT01373281 - Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Phase 3
Completed NCT04048837 - Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore
Completed NCT00468858 - A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children Phase 2
Completed NCT01411241 - Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Phase 3
Completed NCT02824198 - Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule Phase 2